Compare DLO & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLO | STVN |
|---|---|---|
| Founded | 2013 | 1949 |
| Country | Uruguay | Italy |
| Employees | N/A | N/A |
| Industry | Business Services | Containers/Packaging |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.7B |
| IPO Year | 2021 | 2021 |
| Metric | DLO | STVN |
|---|---|---|
| Price | $13.27 | $16.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | $17.25 | ★ $25.67 |
| AVG Volume (30 Days) | ★ 1.7M | 606.3K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.45% | 0.41% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $41.00 | $9.67 |
| Revenue Next Year | $26.98 | $9.99 |
| P/E Ratio | ★ $22.27 | $27.15 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.67 | $12.89 |
| 52 Week High | $16.78 | $28.00 |
| Indicator | DLO | STVN |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 65.59 |
| Support Level | $12.98 | $14.23 |
| Resistance Level | $13.50 | $16.69 |
| Average True Range (ATR) | 0.47 | 0.71 |
| MACD | 0.01 | 0.30 |
| Stochastic Oscillator | 53.64 | 73.26 |
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.